Pure Bioscience (PURE) AI Stock Analysis

• Market Cap: $9.17M
• Dividend Yield: N/A
• Average Volume (3M): 54.73K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.57
• Revenue Growth: -9.48%
• EPS Growth: 15.03%
• Country: US
• Employees: 11
• Sector: Consumer Defensive
• Sector Strength: 63
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 111,886,475
• 10 Day Avg. Volume: 11,133
• 30 Day Avg. Volume: 54,731
• PEG Ratio: 0.25
• Price to Book (P/B): 34.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.86
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.22
• Enterprise Value/Gross Profit: 8.66
• Enterprise Value/Ebitda: -0.77
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Pure Bioscience's overall stock score is low due to severe financial instability, marked by declining revenues and persistent losses. Technical analysis confirms a bearish trend, with all major moving averages indicating downward momentum. Valuation metrics, such as a negative P/E ratio and lack of dividends, further undermine the stock's attractiveness. Immediate strategic and operational improvements are crucial for any potential turnaround.

Pure Bioscience Business Overview & Revenue Model

Company Description

Pure Bioscience (PURE) is a biotechnology company specializing in the development and commercialization of antimicrobial products. The company operates primarily within the health and safety sectors, focusing on solutions that combat bacteria, viruses, and fungi. Its core product, Silver Dihydrogen Citrate (SDC), is a patented, non-toxic antimicrobial agent used in various applications, including food safety, healthcare, and consumer products.

How the Company Makes Money

Pure Bioscience generates revenue through the sale of its proprietary antimicrobial solutions, primarily its Silver Dihydrogen Citrate (SDC) technology. The company targets multiple industries, such as food processing, healthcare, and consumer goods, where there is a high demand for effective and safe antimicrobial agents. Key revenue streams include direct sales to end-users, partnerships with distributors and manufacturers who incorporate SDC into their products, and licensing agreements where third parties pay for the right to use SDC technology in their own offerings. Significant partnerships with companies in the food safety and healthcare sectors bolster its earnings by expanding its market reach and application scope.

Pure Bioscience Financial Statement Overview

Summary

Pure Bioscience is facing significant financial challenges across income, balance sheet, and cash flow statements. The company shows declining revenues, persistent losses, and a deteriorating balance sheet with negative equity and high leverage. Cash flow remains weak, further complicating its financial stability. Immediate strategic interventions are essential to revitalizing its financial health and operational efficiencies.

Income Statement

Pure Bioscience shows a declining revenue trend from 2020 to TTM 2025, with revenue dropping significantly from $6.9M in 2020 to $1.9M in the latest TTM period. Gross profit margins have deteriorated from 58.1% in 2020 to 58.3% in TTM 2025. Net profit margins have been consistently negative, highlighting ongoing losses. The company faces challenges in achieving positive EBIT and EBITDA, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity and rising total debt, reaching $3.98M in TTM 2025. The debt-to-equity ratio is undefined due to negative equity, and the equity ratio is negative, reflecting substantial financial instability. The company's liabilities exceed its assets, indicating potential solvency issues.

Cash Flow

Pure Bioscience is experiencing persistent negative free cash flow, with minimal improvement in operating cash flow. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting sales into cash flow. The free cash flow is negative, indicating ongoing struggles in maintaining liquidity and self-financing operations.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
1.86M	1.96M	1.88M	1.85M	3.93M	6.92M
	Gross Profit
1.08M	1.15M	971.00K	1.00M	2.08M	4.02M
	EBIT
-2.81M	-3.13M	-3.94M	-3.42M	-2.31M	9.00K
	EBITDA
-2.80M	-3.05M	-3.83M	-3.27M	-2.14M	201.00K
	Net Income Common Stockholders
-3.10M	-3.35M	-3.96M	-3.50M	-2.32M	-6.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
202.00K	424.00K	1.09M	3.39M	2.39M	3.84M
	Total Assets
574.00K	818.00K	1.82M	4.48M	4.30M	6.32M
	Total Debt
3.98M	2.95M	1.02M	0.00	239.00K	0.00
	Net Debt
3.77M	2.60M	-74.00K	-3.39M	-2.15M	-3.84M
	Total Liabilities
4.84M	3.68M	1.55M	575.00K	970.00K	1.51M
	Stockholders Equity
-3.40M	-2.86M	272.00K	3.91M	3.33M	4.81M
Cash Flow		Free Cash Flow
-2.25M	-2.53M	-3.31M	-2.50M	-1.69M	611.00K
	Operating Cash Flow
-2.25M	-2.53M	-3.28M	-2.42M	-1.17M	669.00K
	Investing Cash Flow
0.00	0.00	-33.00K	-81.00K	-521.00K	-58.00K
	Financing Cash Flow
1.90M	1.78M	1.01M	3.50M	239.00K	2.83M

Pure Bioscience Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Neutral. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of -9.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PURE.

Pure Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KMB	68 Neutral	$42.46B	17.44	229.84%	3.94%	-3.12%	34.80%
KVUE	68 Neutral	$41.01B	38.95	10.22%	3.84%	-1.18%	-29.18%
CHD	65 Neutral	$23.62B	41.14	13.35%	1.23%	2.18%	-26.08%
Sector *	65 Neutral	$8.73B	15.14	4.69%	4.60%	3.64%	-2.51%
CL	64 Neutral	$71.47B	24.97	977.07%	2.36%	0.98%	12.12%
CLX	64 Neutral	$14.90B	21.72	1176.27%	4.04%	-2.64%	189.29%
PURE	34 Underperform	$9.17M	―	127.81%	―	-9.48%	15.03%